… Despite the acceptance of antifibrotic drug therapy into IPF … on the effect of antifibrotic therapy
on IPF outcomes outside of … of all-cause mortality and acute hospitalizations in antifibrotic-…

… The cause of mortality was compared with a historical cohort. Sarcopenia was assessed by
… The most common cause of mortality in patients receiving AFT was chronic respiratory failure…

… Our findings demonstrate that antifibrotic treatment decreases the risk of all-cause mortality
and AE in patients with IPF. An expected limitation is study heterogeneity with pooled analysis…

… with mortality should be by themselves very good common-sense reasons to start antifibrotic
therapies as … lower risk for all mortality outcomes (all-cause mortality, treatment-emergent all-…

… fibrosis, antifibrotic agents may be associated with a lower risk of all-cause mortality and …
mode of steroid therapy between the untreated and antifibrotic therapy groups could explain …

… to convert this new knowledge into novel and effective anti-fibrotic drugs will be forthcoming
in the near … Novel pathogenesis-based strategies will result in effective anti-fibrotic therapies. …

… Two antifibrotic therapies have been approved for the … with very high morbidity and mortality.
Individual clinical trials have not … of IPF and the utility of antifibrotic therapies, with a focus on …

… Sustained progress in defining the molecular pathophysiology of hepatic fibrosis has led to
a comprehensive framework for developing antifibrotic therapies. Indeed, the single greatest …

… IPF) treated with antifibrotic therapy; however, the initiation or discontinuation of therapy during
… This study investigated the effect of antifibrotic therapy on mortality and other outcomes in …

… controlled trials using mortality as the primary end-point require a large number of patients
and long-term follow-up. This is based on a relatively low all-cause mortality rate among …